

Michael J Donovan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7550610/publications.pdf>

Version: 2024-02-01

82
papers

2,684
citations

279798

23
h-index

197818

49
g-index

86
all docs

86
docs citations

86
times ranked

4734
citing authors

#	ARTICLE	IF	CITATIONS
1	A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. <i>JAMA Oncology</i> , 2016, 2, 882.	7.1	458
2	Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains. <i>Nature Neuroscience</i> , 2014, 17, 121-130.	14.8	239
3	A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen ≥ 10 ng/ml at Initial Biopsy. <i>European Urology</i> , 2018, 74, 731-738.	1.9	186
4	Ageing-like Phenotype and Defective Lineage Specification in SIRT1-Deleted Hematopoietic Stem and Progenitor Cells. <i>Stem Cell Reports</i> , 2014, 3, 44-59.	4.8	135
5	Improved prediction of prostate cancer recurrence through systems pathology. <i>Journal of Clinical Investigation</i> , 2007, 117, 1876-1883.	8.2	102
6	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. <i>European Urology</i> , 2018, 73, 751-759.	1.9	99
7	Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA ≥ 10 ng/mL. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 607-614.	3.9	97
8	Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial. <i>Clinical Cancer Research</i> , 2018, 24, 4937-4948.	7.0	95
9	Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. <i>Gut</i> , 2023, 72, 129-140.	12.1	90
10	Systems Pathology Approach for the Prediction of Prostate Cancer Progression After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2008, 26, 3923-3929.	1.6	85
11	Artificial intelligence in neuropathology: deep learning-based assessment of tauopathy. <i>Laboratory Investigation</i> , 2019, 99, 1019-1029.	3.7	79
12	A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer. <i>Science Advances</i> , 2019, 5, eaav6528.	10.3	74
13	Development and clinical application of an integrative genomic approach to personalized cancer therapy. <i>Genome Medicine</i> , 2016, 8, 62.	8.2	71
14	Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1552-1563.	7.0	65
15	Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease. <i>Diabetologia</i> , 2021, 64, 1504-1515.	6.3	61
16	Personalized Prediction of Tumor Response and Cancer Progression on Prostate Needle Biopsy. <i>Journal of Urology</i> , 2009, 182, 125-132.	0.4	52
17	Urine Exosomes for Non-Invasive Assessment of Gene Expression and Mutations of Prostate Cancer. <i>PLoS ONE</i> , 2016, 11, e0154507.	2.5	48
18	A metastasis biomarker (MetaSite Breast α Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. <i>Npj Breast Cancer</i> , 2017, 3, 42.	5.2	48

#	ARTICLE	IF	CITATIONS
19	Intravoxel incoherent motion diffusion-weighted imaging of hepatocellular carcinoma: Is there a correlation with flow and perfusion metrics obtained with dynamic contrast-enhanced MRI?. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 856-864.	3.4	47
20	Integrated Transcriptome and Network Analysis Reveals Spatiotemporal Dynamics of Calvarial Suturogenesis. <i>Cell Reports</i> , 2020, 32, 107871.	6.4	42
21	Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 296-301.	3.9	40
22	<i>USP8</i> and <i>TP53</i> Drivers are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 826-842.	3.6	34
23	A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3). <i>Gynecologic Oncology</i> , 2020, 157, 188-194.	1.4	34
24	A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy. <i>BMC Urology</i> , 2020, 20, 138.	1.4	29
25	A <i>Drosophila</i> platform identifies a novel, personalized therapy for a patient with adenoid cystic carcinoma. <i>IScience</i> , 2021, 24, 102212.	4.1	23
26	Development and validation of a novel automated Gleason grade and molecular profile that define a highly predictive prostate cancer progression algorithm-based test. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 594-603.	3.9	22
27	Systems pathology. <i>Cancer</i> , 2009, 115, 3078-3084.	4.1	21
28	Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade. <i>Molecular Cancer Research</i> , 2019, 17, 1605-1612.	3.4	21
29	Predicting high-risk disease using tissue biomarkers. <i>Current Opinion in Urology</i> , 2013, 23, 245-251.	1.8	18
30	Effective early detection of oral cancer using a simple and inexpensive point of care device in oral rinses. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 837-844.	3.1	18
31	Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome. <i>World Journal of Urology</i> , 2022, 40, 983-989.	2.2	18
32	A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib. <i>European Journal of Cancer</i> , 2009, 45, 1518-1526.	2.8	15
33	SWI/SNF chromatin remodeling complex alterations in meningioma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3431-3440.	2.5	15
34	Comparative genomic analysis of driver mutations in matched primary and recurrent meningiomas. <i>Oncotarget</i> , 2019, 10, 3506-3517.	1.8	15
35	Initial Validation of a Machine Learning-Derived Prognostic Test (KidneyIntelX) Integrating Biomarkers and Electronic Health Record Data To Predict Longitudinal Kidney Outcomes. <i>Kidney360</i> , 2020, 1, 731-739.	2.1	15
36	Active Cushing Disease Is Characterized by Increased Adipose Tissue Macrophage Presence. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2453-2461.	3.6	13

#	ARTICLE	IF	CITATIONS
37	Peritumoral edema correlates with mutational burden in meningiomas. <i>Neuroradiology</i> , 2021, 63, 73-80.	2.2	13
38	NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 169-176.	4.2	12
39	Recurrent IDH mutations in high-grade meningioma. <i>Neuro-Oncology</i> , 2020, 22, 1044-1045.	1.2	10
40	The development of a Biobank of cancer tissue samples from World Trade Center responders. <i>Journal of Translational Medicine</i> , 2018, 16, 280.	4.4	9
41	Molecular Study of Thyroid Cancer in World Trade Center Responders. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 1600.	2.6	9
42	STK11 mutation status is associated with decreased survival in meningiomas. <i>Neurological Sciences</i> , 2020, 41, 2585-2589.	1.9	9
43	Identification of a novel <i>RASD1</i> somatic mutation in a <i>USP8</i> -mutated corticotroph adenoma. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001602.	1.2	8
44	Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 115-123.	3.8	8
45	Raman Spectroscopy of Head and Neck Cancer: Separation of Malignant and Healthy Tissue Using Signatures Outside the "Fingerprint" Region. <i>Biosensors</i> , 2017, 7, 20.	4.7	8
46	Genomic analysis in active surveillance. <i>Current Opinion in Urology</i> , 2014, 24, 303-310.	1.8	7
47	Analytical validation of a multi-biomarker algorithmic test for prediction of progressive kidney function decline in patients with early-stage kidney disease. <i>Clinical Proteomics</i> , 2021, 18, 26.	2.1	7
48	Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10-year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery. <i>BJU International</i> , 2012, 109, 40-45.	2.5	6
49	Payer budget impact of an artificial intelligence <i>in vitro</i> diagnostic to modify diabetic kidney disease progression. <i>Journal of Medical Economics</i> , 2021, 24, 972-982.	2.1	6
50	1293 PREVIOUSLY DEVELOPED SYSTEMS-BASED BIOPSY MODEL (PROSTATE PX+) IDENTIFIES FAVORABLE-RISK PROSTATE CANCER FOR MEN ENROLLED IN AN ACTIVE SURVEILLANCE PROGRAM. <i>Journal of Urology</i> , 2011, 185, .	0.4	5
51	Predicting and replacing the pathological Gleason grade with automated gland ring morphometric features from immunofluorescent prostate cancer images. <i>Journal of Medical Imaging</i> , 2017, 4, 021103.	1.5	5
52	Gland Ring Morphometry for Prostate Cancer Prognosis in Multispectral Immunofluorescence Images. <i>Lecture Notes in Computer Science</i> , 2014, 17, 585-592.	1.3	5
53	Transgenic drosophila as a drug-screening platform in colorectal cancer and medullary thyroid cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23164-e23164.	1.6	4
54	Association of mutations in DNA polymerase epsilon with increased CD8+ cell infiltration and prolonged progression-free survival in patients with meningiomas. <i>Neurosurgical Focus</i> , 2022, 52, E7.	2.3	4

#	ARTICLE	IF	CITATIONS
55	Artificial intelligence methods for predictive image-based grading of human cancers. , 2021, , 175-210.		3
56	In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study.. Journal of Clinical Oncology, 2016, 34, 3086-3086.	1.6	3
57	A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.. Journal of Clinical Oncology, 2019, 37, 9538-9538.	1.6	3
58	Global DNA methylation of WTC prostate cancer tissues show signature differences compared to non-exposed cases. Carcinogenesis, 2022, 43, 528-537.	2.8	3
59	Overcoming tumor heterogeneity in the molecular diagnosis of urological cancers. Expert Review of Molecular Diagnostics, 2014, 14, 1023-1031.	3.1	2
60	Interim performance of a non-DRE urine exosome gene signature to predict Gleason ≥ 7 prostate cancer on initial prostate needle biopsy from patients enrolled in a prospective observational trial.. Journal of Clinical Oncology, 2015, 33, 5064-5064.	1.6	2
61	A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies.. Journal of Clinical Oncology, 2019, 37, e14307-e14307.	1.6	2
62	2053 URINARY EXOSOMES/MICROVESICLES AS A NON-INVASIVE PLATFORM FOR PROSTATE CANCER ANALYSIS. Journal of Urology, 2013, 189, .	0.4	1
63	Multiple immunofluorescence assay identifies upregulation of Active β -catenin in prostate cancer. BMC Research Notes, 2019, 12, 68.	1.4	1
64	Window of opportunity trial of HPV E7 antigen-expressing Listeria-based therapeutic vaccination prior to robotic surgery for HPV-positive oropharyngeal cancer.. Journal of Clinical Oncology, 2015, 33, TPS6088-TPS6088.	1.6	1
65	Extended analysis of a validated urine-exosome signature to predict high grade prostate cancer on initial biopsy: Performance across multiple sub-groups.. Journal of Clinical Oncology, 2016, 34, 42-42.	1.6	1
66	Performance of a validated urine exosome gene expression assay to predict high-grade prostate cancer utilizing the International Society of Urological Pathology (ISUP) 2014 grading system.. Journal of Clinical Oncology, 2017, 35, 49-49.	1.6	1
67	Prostate cancer prognosis via integrative and co-localized glandular morphometry and immunofluorescent protein biomarker expression.. Journal of Clinical Oncology, 2015, 33, 262-262.	1.6	1
68	A quantitative image analysis model of prostate biopsies for predicting clinical risk in men enrolled in an active surveillance program.. Journal of Clinical Oncology, 2014, 32, 111-111.	1.6	0
69	A quantitative image analysis model of prostate biopsies for predicting clinical risk in men enrolled in an active surveillance program.. Journal of Clinical Oncology, 2014, 32, e16002-e16002.	1.6	0
70	Association of elevated levels of AR and PAKT in the diagnostic prostate needle biopsy with a greater risk for disease progression: Implications for prognostic models and future treatment decision making.. Journal of Clinical Oncology, 2014, 32, e16007-e16007.	1.6	0
71	Genomic analysis and personalized cancer therapy for metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 568-568.	1.6	0
72	Incorporation of advanced image analysis in novel post-prostatectomy systems pathology models as an approach to replace the clinical Gleason and provide robust risk stratification.. Journal of Clinical Oncology, 2015, 33, e16134-e16134.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Advanced tissue-based image analysis techniques integrated with biomarker-morphometric multiplex immunofluorescence to provide prostate cancer risk stratification models post-surgery.. Journal of Clinical Oncology, 2016, 34, 47-47.	1.6	0
74	A non-invasive urine exosome gene expression assay (ExoIntelliScore Prostate) to predict pathologic stage and grade in the prostatectomy specimen.. Journal of Clinical Oncology, 2016, 34, 46-46.	1.6	0
75	Successful development of a first in class tissue-based morphometric approach to re-define prostate cancer Gleason grading and improve risk discrimination at the time of diagnosis.. Journal of Clinical Oncology, 2016, 34, e16610-e16610.	1.6	0
76	Clinical outcomes in genetically targeted cancer treatment.. Journal of Clinical Oncology, 2016, 34, e23127-e23127.	1.6	0
77	Tissue-based analytics provide the next generation of prostate cancer risk models.. Journal of Clinical Oncology, 2017, 35, 236-236.	1.6	0
78	Trials in progress: A phase II study of in situ therapeutic vaccination against refractory solid cancers with intratumoral poly-ICLC.. Journal of Clinical Oncology, 2017, 35, 166-166.	1.6	0
79	Prospective serial sequencing of CTC/cfDNA and NK cell activity in patients undergoing multimodality treatment for triple negative breast cancer.. Journal of Clinical Oncology, 2018, 36, e24108-e24108.	1.6	0
80	Performance of a validated urine exosome gene expression test (EPI) in men within the USPSTF suggested age-group of 55 to 69 years at initial biopsy with a PSA 2-10 ng/mL.. Journal of Clinical Oncology, 2019, 37, 53-53.	1.6	0
81	Spectroscopic analysis with a monolithic micro-structured microsphere fiber probe. , 2019, , .		0
82	289â€™..PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting. , 2020, , .		0